Salemonline Journal

The Amyotrophic Lateral Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Amyotrophic Lateral Sclerosis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Amyotrophic Lateral Sclerosis Market.

Some of the key takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Amyotrophic Lateral Sclerosis treatment therapies with a considerable amount of success over the years. 
• Amyotrophic Lateral Sclerosis companies working in the treatment market are Aeterna Zentaris, GeNeuro SA, ProJenX, QurAlis Corporation, Wave Life Sciences, Revalesio Corporation, AI THERAPEUTICS, CYTOKINETICS, Ionis Pharmaceuticals, and others, are developing therapies for the Amyotrophic Lateral Sclerosis treatment 

• Emerging Amyotrophic Lateral Sclerosis therapies in the different phases of clinical trials are- AEZS-130, GNK 301, Prosetin, QRL 201, WVE-004, RNS60, AIT-101, Reldesemtiv, ION363, and others are expected to have a significant impact on the Amyotrophic Lateral Sclerosis market in the coming years.   
• In December 2023, NeuroSense Therapeutics announced positive outcomes from the Phase IIb PARADIGM clinical trial of its medication candidate, PrimeC, in individuals with amyotrophic lateral sclerosis (ALS). The trial successfully achieved its primary and secondary objectives. This double-blind, randomized, multinational, and placebo-controlled study evaluated PrimeC in ALS patients across Israel, Canada, and Italy over a six-month period.
• In November 2023, ProJenX, a biotechnology company in the clinical stage, is pioneering the development of innovative therapies that can penetrate the brain and target biologically-defined pathways for treating amyotrophic lateral sclerosis (ALS) and other severe brain disorders. Today, the company announced that Health Canada has granted authorization for its clinical trial application (CTA) for study PRO-101. This global, hybrid Phase 1 clinical trial will assess prosetin, a pioneering MAP4K inhibitor, in both healthy volunteers and individuals with ALS. The Health Canada CTA approval facilitates the commencement of Part 1c of PRO-101, which is tailored to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of prosetin in participants with ALS.
• In September 2022, The FDA in the United States sanctioned RELYVRIO for ALS. This medication combines sodium phenylbutyrate and taurursodiol, demonstrating a decrease in the rate of decline in daily functioning during clinical assessments and correlating with extended overall survival.
• In July 2022, Cytokinetics has started a Phase III Open-Label Extension trial called CY5032, following the completion of dosing (up to Week 48) in CY5031 (COURAGE-ALS). This study involves reldesemtiv, a selective fast skeletal muscle troponin activator, and aims to include approximately 400 ALS patients from the sites previously involved in CY5031 for the open-label extension, CY5032.
• In April 2023, AI Therapeutics, Inc., has reported favorable outcomes from a Phase 2a clinical study involving AIT-101 (LAM002A) in individuals with C9ORF72 amyotrophic lateral sclerosis (ALS). Participants receiving AIT-101 exhibited elevated expression of the target engagement biomarker (sGPNMB) and a 73% decrease in the toxic protein aggregate (poly(GP)) over a span of 12 weeks. Additionally, the study achieved its primary goals of establishing safety and tolerability, as well as confirming the delivery of the drug and three active metabolites into the brain.

Amyotrophic Lateral Sclerosis Overview

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disorder that affects nerve cells in the brain and spinal cord. ALS leads to the gradual deterioration and death of motor neurons, which are the nerve cells responsible for controlling voluntary muscle movement. 

Get a Free Sample PDF Report to know more about Amyotrophic Lateral Sclerosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight

Emerging Amyotrophic Lateral Sclerosis Drugs Under Different Phases of Clinical Development Include:

• AEZS-130: Aeterna Zentaris
• GNK 301: GeNeuro SA
• Prosetin: ProJenX
• QRL 201: QurAlis Corporation
• WVE-004: Wave Life Sciences
• RNS60: Revalesio Corporation
• AIT-101: AI THERAPEUTICS
• Reldesemtiv: CYTOKINETICS
• ION363: Ionis Pharmaceuticals

Amyotrophic Lateral Sclerosis Route of Administration

Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Amyotrophic Lateral Sclerosis Molecule Type

Amyotrophic Lateral Sclerosis Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Amyotrophic Lateral Sclerosis Pipeline Therapeutics Assessment

• Amyotrophic Lateral Sclerosis Assessment by Product Type
• Amyotrophic Lateral Sclerosis By Stage and Product Type
• Amyotrophic Lateral Sclerosis Assessment by Route of Administration
• Amyotrophic Lateral Sclerosis By Stage and Route of Administration
• Amyotrophic Lateral Sclerosis Assessment by Molecule Type
• Amyotrophic Lateral Sclerosis by Stage and Molecule Type

DelveInsight’s Amyotrophic Lateral Sclerosis Report covers around 100+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Amyotrophic Lateral Sclerosis product details are provided in the report. Download the Amyotrophic Lateral Sclerosis pipeline report to learn more about the emerging Amyotrophic Lateral Sclerosis therapies

Some of the key companies in the Amyotrophic Lateral Sclerosis Therapeutics Market include:

Key companies developing therapies for Amyotrophic Lateral Sclerosis are – Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis Pharmaceuticals, Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, Seelos Theraputics, Prilenia Therapeutics, AB Science, Eledon Pharmaceuticals, Revalesio Corporation, Biohaven Pharmaceuticals, UCB Pharma, Ra Pharmaceuticals, AI Therapeutics, and others.

Amyotrophic Lateral Sclerosis Pipeline Analysis:

The Amyotrophic Lateral Sclerosis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Amyotrophic Lateral Sclerosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Amyotrophic Lateral Sclerosis Treatment.
• Amyotrophic Lateral Sclerosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Amyotrophic Lateral Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Amyotrophic Lateral Sclerosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Amyotrophic Lateral Sclerosis drugs and therapies

Amyotrophic Lateral Sclerosis Pipeline Market Drivers

• Need for disease-specific treatment options, rising geriatric population, increasing research and developmental activities are some of the important factors that are fueling the Amyotrophic Lateral Sclerosis Market.

Amyotrophic Lateral Sclerosis Pipeline Market Barriers

• However, No standard cure for ALS, unknown cause of the disease and other factors are creating obstacles in the Amyotrophic Lateral Sclerosis Market growth.

Scope of Amyotrophic Lateral Sclerosis Pipeline Drug Insight    

• Coverage: Global
• Key Amyotrophic Lateral Sclerosis Companies: Aeterna Zentaris, GeNeuro SA, ProJenX, QurAlis Corporation, Wave Life Sciences, Revalesio Corporation, AI THERAPEUTICS, CYTOKINETICS, Ionis Pharmaceuticals, and others
• Key Amyotrophic Lateral Sclerosis Therapies: AEZS-130, GNK 301, Prosetin, QRL 201, WVE-004, RNS60, AIT-101, Reldesemtiv, ION363, and others
• Amyotrophic Lateral Sclerosis Therapeutic Assessment: Amyotrophic Lateral Sclerosis current marketed and Amyotrophic Lateral Sclerosis emerging therapies
• Amyotrophic Lateral Sclerosis Market Dynamics: Amyotrophic Lateral Sclerosis market drivers and Amyotrophic Lateral Sclerosis market barriers 

Request for Sample PDF Report for Amyotrophic Lateral Sclerosis Pipeline Assessment and clinical trials

Table of Contents

1. Amyotrophic Lateral Sclerosis Report Introduction

2. Amyotrophic Lateral Sclerosis Executive Summary

3. Amyotrophic Lateral Sclerosis Overview

4. Amyotrophic Lateral Sclerosis- Analytical Perspective In-depth Commercial Assessment

5. Amyotrophic Lateral Sclerosis Pipeline Therapeutics

6. Amyotrophic Lateral Sclerosis Late Stage Products (Phase II/III)

7. Amyotrophic Lateral Sclerosis Mid Stage Products (Phase II)

8. Amyotrophic Lateral Sclerosis Early Stage Products (Phase I)

9. Amyotrophic Lateral Sclerosis Preclinical Stage Products

10. Amyotrophic Lateral Sclerosis Therapeutics Assessment

11. Amyotrophic Lateral Sclerosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Amyotrophic Lateral Sclerosis Key Companies

14. Amyotrophic Lateral Sclerosis Key Products

15. Amyotrophic Lateral Sclerosis Unmet Needs

16 . Amyotrophic Lateral Sclerosis Market Drivers and Barriers

17. Amyotrophic Lateral Sclerosis Future Perspectives and Conclusion

18. Amyotrophic Lateral Sclerosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/